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Hypereosinophilic syndrome (HES) is a systemic illness that usually presents with
nonspeciﬁc symptoms. However, HES can be fatal, particularly when eosinophils inﬁltrate
vital organs. We report a patient with HES who presented with a perforated viscus and
sepsis-like syndrome and rapidly improved with drotrecogin-alfa and steroid therapy.
& 2008 Elsevier Ltd. All rights reserved.Case
A 52 yr old male with a 5-month history of fever and fatigue
presented to an outside hospital (OSH) with cough and
debilitating abdominal pain. He promptly underwent an
exploratory laprotomy, which revealed a small colonic
perforation. A portion of bowel was resected and repaired
with end to end anastomosis. He was reintubated soon after
surgery for increasing hypoxemia and transferred to our
institution.
On transfer, the patient was afebrile with a pulse rate of
122. His oxygen saturation was 92% on FiO2 100% and PEEP of
15 cmH2O. His blood pressure was 96/46 while receiving
norepinephrine at 10mcg/min. His cardiac exam revealed
tachycardia without murmur. Lungs demonstrated bilateralElsevier Ltd. All rights reserved.
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(K.S. Knox).crackles. Abdomen was soft and nontender, with a clean
midline scar. His skin appeared ﬂushed. The rest of the exam
was normal.
WBC count was 36.0 103 cells/mm3, hemoglobin concen-
tration was 9.4gm/dL, and platelet count was 289,000/mm3.
WBC differential (automated) was 57% neutrophils, 27%
bands, 6% eosinophils, and 10% lymphocytes. The chemistry
demonstrated a sodium of 148, chloride 106, HCO3 35, BUN
36, creatinine 1.0, and calcium of 8.0. All other chemistry
values were normal. The AST was 32. Serum troponin was
25ng/mL (normal: 0–0.5ng/mL). The admission chest radio-
graph demonstrated diffuse bilateral air space disease with
mild cardiomegaly.
Cultures were obtained from blood, urine, and sputum.
Drotrecogin alfa (activated) and broad-spectrum antibiotics
were given. Over the next 24 h, the patient’s oxygen
requirement decreased signiﬁcantly (FiO2 50%, PEEP
8 cm H2O), and blood pressure was 122/70 off pressors.
However, his peripheral blood smears were manually
reviewed and demonstrated a peripheral eosinophil count
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as bands initially). By 72 h, his troponin levels returned to
normal. Echocardiogram at the outside institution had
demonstrated regional hypokinesis, but repeat evaluation
showed normal ventricular function. CT scan of the chest
demonstrated extensive ground-glass opacities and bibasilar
inﬁltrates (Figure 1). As he was unable to wean from
mechanical ventilation, bronchoscopy with bronchoalveolar
lavage day 3 of transfer showed a few alveolar macrophages
and 94% eosinophils (Figure 2).
Records obtained revealed that the patient had eosino-
philia (18% of the total WBCs) at an outpatient evaluation
for fatigue 4 months earlier. Histology slides from his colon
resection were obtained and showed a marked eosinophilic
inﬁltration with evidence of eosinophilic vasculitis. Bone
marrow biopsy was eventually performed to exclude
eosinophilic leukemia and showed eosinophilic precursors
and no blasts. Antibiotics were stopped, but eosinophiliaFigure 1 CT scan after drotrecogin alpha therapy. Despite
rapid improvement in compliance and gas exchange, inﬁltrates
persist and BAL is performed.
Figure 2 Cytospin of bronchoalveolar lavage shows one large
alveolar macrophage with several surrounding eosinophils (Diff-
Quik 400 ).persisted. No drug reaction, parasitic infection, or auto-
antibodies were detected. Genetic testing was negative.
Flow cytometry was negative for hematologic malignancy.
Idiopathic hypereosinophilic syndrome (HES) with lung,
colon, and cardiac involvement was diagnosed and the
patient was started on methylprednisolone (60mg IV q6)
and hydroxyurea. The patient was extubated 24 h after the
initiation of steroids. He did well over the next few days and
was discharged home on 40mg of prednisone. His WBC count
at the time of discharge was 24,000 with 14% eosinophils.Discussion
Idiopathic HES is a systemic illness with the pathological
hallmark of eosinophil inﬁltration in affected organs. The
classic diagnostic criteria include (1) blood eosinophilia of
41500 cells/mm3 for 4 months, (2) no other apparent
etiologies for eosinophilia, and (3) evidence of end-organ
dysfunction. However, as technology now permits research-
ers to more rigorously deﬁne autoimmune syndromes,
cellular clonality, and genetic mutations associated with
HES, the number of cases deﬁned as ‘‘idiopathic’’ is
declining. Common presenting symptoms include fatigue,
cough, dyspnea, fever, myalgia, and rash. HES often involves
the skin, heart, lungs, nervous system, and spleen.1,2
Eosinophilic myocarditis is a major cause of morbidity and
mortality among patients with HES. It is characterized by
myocardial inﬁltration with eosinophils and lymphocytes
followed by myocardial necrosis. Common cardiac presenta-
tions include heart failure, chest pain, arrhythmia, and
cardiac thrombi. As the disease progresses, chronic mani-
festations of restrictive cardiac disease secondary to wide-
spread ﬁbrosis can occur.2,3
Pulmonary involvement varies signiﬁcantly. Chronic, dry,
insidious cough is a frequent complaint of those diagnosed
with HES. However, eosinophilic inﬁltration into the pul-
monary parenchyma may lead to focal or more widespread
inﬁltrates. Pleural effusions can occur. Pulmonary emboli
are common in HES, and result from endothelial damage
secondary to local eosinophil degranulation and tissue
necrosis. Because of the tendency toward thrombosis,
anticoagulation is advocated by some for this disorder.1,2
Corticosteroids are the mainstay of treatment for acutely
ill patients with HES. Most patients achieve a rapid and
signiﬁcant decrease in the number of circulating eosinophils
and the reversible organ dysfunction usually improves
quickly. Achieving long-term control of the disease has
proven more difﬁcult. As underlying etiologies of HES are
discovered, targeted therapies may be beneﬁcial. For
example, those patients with a FIP1L1/PDGFRA (Fip1-like
1/platelet-derived growth factor receptor alpha) mutation
have been shown to beneﬁt from treatment with tyrosine
kinase inhibitors.4–6
Unique to this report, our patient was given drotrecogin-
alfa for his sepsis-like syndrome, which was likely to be due
to HES. Other reports have documented the hypothetical use
of drotrecogin alfa in other eosinophil-mediated disorders,
though evidence is sparse.7–9 This report should alert
clinicians that HES can mimic sepsis and vasculitis. Prompt
diagnosis and treatment with corticosteroids can result in
favorable outcomes.
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